جستجوی مقالات مرتبط با کلیدواژه « systemic lupus erythematous (sle) » در نشریات گروه « پزشکی »

This study evaluates the effects of combining aerobic running and anaerobic Pilates exercises to reduce fatigue improve cardiovascular and muscular fitness, and enhance the quality of life (QoL) in systemic lupus erythematosus (SLE) patients.

A total of 19 SLE patients with index SLE disease activity index (SLEDAI) scores ≤4 were randomly assigned into an intervention group (n=10), undertaking the combined exercise program, and a control group (n=9), undertaking normal activities of daily living only. The combined exercise program lasted 8 weeks and consisted of three 1-h weekly sessions. In both groups, functional capacity, cardiovascular fitness, muscle endurance capacity and QoL were assessed before and following the programmed activity or ADL only. The data were analyzed by the SPSS software, version 18 at the significance level of 0.05.

The results confirm that this combined exercise program provides significant benefits over activities of daily living concerning pre-test and post-test difference scores for functional capacity (VO2peak 1.86±1.45 vs -0.95±1.43 mL/min/kg, P<0.01). Significant benefits were also observed for the number of sit-ups achieved (11.30±9.91 vs 0.5±1.06, P<0.01), sit and reach improvements (6.92±5.09 vs 0.5±0.92 cm, P<0.05), subjective fatigue (-3.38±5.59 vs 1.75±1.48, P<0.05), and regarding the overall mean of summed QoL subscales scores (10.80±4.90 vs 0.06±1.56).

Combining aerobic and anaerobic exercises can mitigate subjective fatigue and significantly improve functional capacity, myocardial metabolism, muscular endurance, flexibility, and QoL in SLE patients.

risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite the effectiveness of usingcombined conventional and biological disease-modifying anti-rheumatic drugs(bDMARDs) in managing rheumaticdiseases, there have been concerns that taking biological agents may have an additive effect on getting infected withCOVID-19. This study evaluates the impact of taking biological agents on altering the chance of getting infected withSARS-CoV-2 in rheumatoloid and lupus patients compared to traditional DMARDs.

We carried out a cross-sectional survey study from February 2020 to January 2021 on patients diagnosedwith lupus and rheumatid arthritis. COVID-19 infection was confirmed by the presence of symptoms and signs of the diseaseand para-clinical findings such as lymphopenia and elevated C-reactive protein (CRP) and positive chest CT scanor polymerase chain reaction (PCR) of COVID-19.

Out of 591 patients included in this study, 422 (71.4%) had rheumatoid arthritis (RA), and 169 (28.6%) hadsystemic lupus erythematosus (SLE). Among them, 56 (9.5%) cases were diagnosed with COVID-19 infection. Noassociation was found between age, gender, or type of rheumatological diseases and SARS-CoV-2. There was asignificant association between COVID-19 infection and treatment with biological drugs (P-value<0.05) regardless ofthe type of rheumatologic disease. Interestingly, the analysis revealed that the type of biologic drug also altered thechance of COVID-19 infection; In fact, patients who took TNF inhibitors were significantly at a higher risk of diseasethan those taking Rituximab (P-value=0.000). Identical results were observed among RA patients (P-value<0.001),however, all 5 (3%) lupus cases treated with Rituximab infected with covid 19.

This study develops a better understanding of the risk of immunosuppressive medications for SARSCoV-2 infection. Patients treated with conventional and biological medicine had a higher disease risk than those takingexclusively conventional drugs. However, more studies are required to deliberate the relation of the reviewed factorswith the severity of COVID-19.Level of evidence: II